[Which patient for TAVI in 2019?]

G Cayla; L Schmutz; C Soullier; J E Ricci; C Robert; M Cambon-Viala; A L Goger; B Lattuca

doi:10.1016/j.ancard.2019.10.002

[Which patient for TAVI in 2019?]

Ann Cardiol Angeiol (Paris). 2019 Dec;68(6):405-409. doi: 10.1016/j.ancard.2019.10.002. Epub 2019 Oct 25.

[Article in French]

Authors

G Cayla¹, L Schmutz², C Soullier², J E Ricci², C Robert², M Cambon-Viala², A L Goger², B Lattuca²

Affiliations

¹ Service de cardiologie, université de Montpellier, CHU de Nîmes, 30029 Nîmes, France. Electronic address: [email protected].
² Service de cardiologie, université de Montpellier, CHU de Nîmes, 30029 Nîmes, France.

PMID: 31668846
DOI: 10.1016/j.ancard.2019.10.002

Abstract

The therapeutic management of aortic stenosis has been drastically changed by the advent of percutaneous valve replacement (TAVI). Since the first implantation, the indications have progressively been extended from the inoperable patient to the patient at low surgical risk. The main objective of this review is to describe the currently recommended main indications of TAVI depending on an individualized assessment of each patient's risk, technical characteristics and anatomical valvular criteria.

Keywords: Aortic stenosis; Heart team; Indications; Rétrécissement aortique; TAVI; Transcatheter valve implantation; Valve aortique percutanée.

Publication types

Review

MeSH terms

Aortic Valve / pathology
Aortic Valve Stenosis / complications
Aortic Valve Stenosis / pathology
Aortic Valve Stenosis / surgery*
Contraindications, Procedure
Heart Valve Prosthesis
Heart Valve Prosthesis Implantation
Humans
Patient Selection*
Practice Guidelines as Topic
Prosthesis Failure
Reoperation
Risk Assessment
Transcatheter Aortic Valve Replacement / adverse effects
Transcatheter Aortic Valve Replacement / methods*